Fig. 1
Peripheral inoculations of spinal cord homogenate from paralytic end-stage hSOD1G85R mice do not induce premature ALS in Tg mice. a–c Experimental overview: ~ 100-day-old pre-symptomatic hSOD1G85R Tg ALS-model mice were inoculated with spinal cord tissue homogenates from either end-stage paralytic hSOD1G85R Tg mice or control non-Tg C57BL/6 mice. We administrated the homogenates a into the spinal cord (spc) (single inoculation into the left ventral horn of the lumbar spinal cord, 1 µl), b i.p. (two inoculations into the peritoneal cavity, 150 µl each, 1 week apart), and c i.m. (single inoculation into the right quadriceps femoris muscle, 10 µl). d–f Kaplan–Meier plots show the survival of the spinal cord homogenate inoculated hSOD1G85R Tg mice. As a reference, the plots contain survival data for non-inoculated hSOD1G85R Tg mice. d Concentration-dependent induction of premature fatal motor neuron disease after intraspinal inoculation of the Tg homogenate. Survival of hSOD1G85R Tg mice after spinal cord inoculation of an undiluted 10% homogenate from end-stage hSOD1G85R Tg spinal cord and 1:3, 1:9 and 1:27 dilutions, compared to inoculation with control extract